6,595 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Purchased by Correct Capital Wealth Management

Correct Capital Wealth Management acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 6,595 shares of the medical equipment provider's stock, valued at approximately $644,000.

Other hedge funds also recently modified their holdings of the company. Summit Securities Group LLC bought a new stake in Lantheus during the 4th quarter valued at $37,000. UMB Bank n.a. increased its stake in Lantheus by 68.2% during the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after purchasing an additional 381 shares in the last quarter. Blue Trust Inc. increased its stake in Lantheus by 117.7% during the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock valued at $114,000 after purchasing an additional 633 shares in the last quarter. 1620 Investment Advisors Inc. bought a new stake in Lantheus during the 4th quarter valued at $125,000. Finally, GAMMA Investing LLC increased its stake in Lantheus by 29.3% during the 1st quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider's stock valued at $128,000 after purchasing an additional 298 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Lantheus Stock Up 0.4%

Shares of NASDAQ LNTH traded up $0.34 during trading on Thursday, hitting $83.83. The stock had a trading volume of 814,865 shares, compared to its average volume of 1,001,940. Lantheus Holdings, Inc. has a 12 month low of $73.11 and a 12 month high of $126.89. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46. The company has a market capitalization of $5.80 billion, a PE ratio of 23.82 and a beta of 0.12. The firm has a fifty day moving average of $80.81 and a two-hundred day moving average of $90.01.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). The firm had revenue of $372.76 million during the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The business's revenue was up .8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.69 EPS. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on LNTH shares. Truist Financial decreased their price target on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, B. Riley decreased their price target on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research note on Monday, June 23rd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $130.50.

Insider Buying and Selling at Lantheus

In related news, Director Mary Anne Heino sold 26,066 shares of the business's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the transaction, the director directly owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. The trade was a 7.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.50% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.